Vyome Holdings (NASDAQ: HIND) has announced it will present its full Phase 2 investigator-initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of malignant fungating wounds (MFW) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego.
According to Vyome, the research will be presented at the “Phase 2 and Phase 3 Clinical Trials in Progress” session of the AACR annual meeting.
In a statement, Venkat Nelabhotla, CEO of Vyome, commented, “There are currently no FDA approved drugs to treat malodor and other symptoms of MFW. We plan to have FDA interactions in Q2 2026 on the pivotal study design. Recent third-party analysts estimated the total addressable U.S. market to be approximately USD 2.2 billion. Inflammation is one of the biggest healthcare problems facing the world today.”
